Treatment of autoimmune diseases.
Therapeutic applications
After transplantation, acute or chronic antibody-mediated rejection can lead to organ loss. In many cases where such rejection reactions do not respond sufficiently to drugs, they may be rapidly and effectively interrupted by an apheresis procedure like therapeutic plasma exchange orÌýimmunoadsorption.1ÌýIn patients with an increased risk of transplant rejection, a preventive removal of antibodies against histocompatibility or blood group antigens using immunoadsorption is a proven established modality.2Ä¢¹½´«Ã½‘5
Indications to be considered for therapeutic apheresis treatments (based on individualized decision making) include:25,26
- Nephritis associated with infections or systemic disorders
- Primary or idiopathic membranous nephropathy6
- Rapidly progressive glomerulonephritis (RPGN)7
- GoodpastureÄ¢¹½´«Ã½™s syndrome7
- Recurrent focal segmental glomerulosclerosis (FSGS)8Ä¢¹½´«Ã½‘10
Ìý
GLOBAFFIN
Effective broad-spectrum immunoadsorption
In addition to pemphigus vulgaris, therapeutic apheresis can potentially be used to treat the following diseases:13Ä¢¹½´«Ã½‘15
- Pemphigus foliaceus
- Bullous pemphigoid
- Pemphigoid gestationis
- Epidermolysis bullosa aquisita
Ìý
GLOBAFFIN
Effective broad-spectrum immunoadsorption
To decrease the high plasma levels of IgG that play a major role in many neurological diseases, patients can be treated either through the use of immunoadsorption techniques that selectively reduce IgG or with plasma exchange, which is a rather unselective method.
The use of therapeutic plasma exchange or immunoadsorption to remove antibodies can be considered for intervention in the acute exacerbation of autoimmune diseases and in patients who do not respond, or only weakly respond, to immunosuppressive therapy.19,21
In addition to the mentioned indications, therapeutic apheresis can also be applied to:
- Chronic inflammatory demyelinating polyneuropathy (CIDP)Ìý22,23,25
- Lambert-Eaton syndromeÌý24,25
Ìý
GLOBAFFIN
Effective broad-spectrum immunoadsorption
As preliminary reports have indicated, rheopheresis may be considered as a promising treatment option for patients with non-healing ulcerative wounds caused by PVD or diabetes mellitus, after standard therapy has failed (data only available from case reports and small series).25,30Ä¢¹½´«Ã½‘32
In patients with dilated cardiomyopathy caused by autoantibodies, administration of five sessions ofÌýimmunoadsorptionÌýon consecutive days may lead to a long-term improvement of clinical parameters and cardiac function.33Ä¢¹½´«Ã½‘35
DALI Adsorbers
Semi-selective and effective lipoprotein adsorbers
MONET Plasma Fractionator
Filter for effective reduction of high molecular weight plasma components
Medical information
Therapeutic apheresisÌýin COVID-19
PDF, 84 KBRelated content
1ÌýBöhmig GA et al. Am J Transplant 2007; 7:117-121
2ÌýSchwaiger E et al. Nephrol Dial Transplant 2016; 31(8):1342-1351
3ÌýMorath C et al. Transpl Int 2012; 25(5):506-517
4ÌýBartel G et al. Am J Transplant 2010; 10(9):2033-2042
5ÌýThölking G et al. PLoS One 2015; 10(6):e0131465
6ÌýHamilton P et al. J Clin Apher 2022; 37:40-53
7ÌýBiesenbach P et al. PLoS One 2014; 9(7):e103568
8ÌýDantal J et al. N Engl J Med 1994; 330(1):7-14
9ÌýMoriconi L et al. Ren Fail 2001; 23(3-4):533-541
10ÌýMeyer TN et al. Transpl Int 2007; 20(12):1066-1071
11ÌýEming R et al. Dermatology 2006; 212(2):177-187
12ÌýHübner F et al. J Dtsch Dermatol Ges 2018; 16(9):1109-1118
13ÌýMeyersburg D et al. Ther Apher Dial 2012; 16(4):311-320
14ÌýEming R et al. Autoimmunity 2006; 39(7):609-616
15ÌýKridin K et al. Dermatol Clin 2019; 37:215Ä¢¹½´«Ã½“228
16ÌýSeta T et al. Clin Neurol Neurosurg 2005; 107:491-496
17ÌýBenny WB et al. Transfusion 1999; 39:682-687
18ÌýDogan Onugoren M et al. Neurol Neuroimmunol Neuroinflamm 2016; 26; 3(2):e207
19ÌýDorst J et al. EClinicalMedicine 2019; 16:98-106
20ÌýHempel P et al. Ther Apher Dial 2016; 20(5):523-529
21ÌýDorst J et al. J Mult Scler (Foster City) 2016; 3:178
22ÌýDorst J et al. J Neurol 2018; 265:2906-2915
23ÌýRech J et al. Ther Apher Dial. 2008;12(3):205-208
24ÌýBaggi F et al. J Neuroimmunol. 2008;201-202:104-110
25ÌýPadmanabhan A et al. J Clin Apher 2019; 34:171-354
26ÌýChen YY et al. Ren Fail 2022; 44:842-857
27ÌýRichtlinie Methoden vertragsärztliche Versorgung; BAnz AT 30.03.2021 B4
28ÌýHeigl F et al. Atheroscler Suppl 2019;40:23-29
29ÌýKosmadakis G Int J Artif Organs 2022;45(5):445-454
30ÌýMehdi et al. Nephrol Dial Transplant 2019;34(S1):i234Ä¢¹½´«Ã½“ i235
31ÌýPithova et al. Poster presented at the DFSG congress; 2017 Sept 8-10; Porto, Portugal
32ÌýSoltész et al. Orv Hetil 2021;162(10):375Ä¢¹½´«Ã½“382
33ÌýWeinmann K et al. Biomolecules. 2018; 8(4):133
34ÌýStaudt et al. Clin Pharmacol Ther. 2010; 87(4):452-458
35ÌýDandel M et al. Eur J Heart Fail. 2012; 14(12):1374-1388